SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild,Alfred Zippelius,E.I. Eboulet,Spasenija Savic Prince,Daniel Betticher,Adrienne Bettini,Martin Früh,Markus Joerger,Didier Lardinois,Hans Gelpke,Laetitia A. Mauti,Christian Britschgi,Walter Weder,Solange Peters,Michael Mark,Richard Cathomas,Adrian F. Ochsenbein,Wolf-Dieter Janthur,Christine Waibel,Nicolas Mach,Patrizia Froesch,Martin Buess,Pierre Bohanes,Gilles Godar,Corinne Rusterholz,Michel Gonzalez,Miklos Pless

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

2021

PURPOSEFor patients with resectable stage IIIA(N2) non–small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EF...

Keywords:

Internal medicine
non small cell
in patient
Stage IIIa
Medicine
Oncology
Lung cancer
Durvalumab
Cisplatin
Docetaxel
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations